Advances in the treatment of clostridium difficile with fidaxomicin: A narrow spectrum antibiotic

Annals of the New York Academy of Sciences

Volumn 1291, Issue 1, 2013, Pages 33-41

  Sears, Pamela ^a   Ichikawa, Yoshi ^a   Ruiz, Nancy ^a   Gorbach, Sherwood ^a  

^a Optimer Pharmaceuticals Inc   (United States)

Author keywords

CDAD; CDI; Clostridium difficile; Fidaxomicin

Indexed keywords

FIDAXOMICIN; RNA POLYMERASE; VANCOMYCIN;

ABDOMINAL DISTENSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FLATULENCE; FOLLOW UP; HUMAN; INTESTINE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MESSENGER RNA SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA; PUBLIC HEALTH; RECURRENT DISEASE; SIDE EFFECT; TREATMENT RESPONSE; UNITED STATES; VOMITING; XEROSTOMIA;

CLOSTRIDIUM DIFFICILE;

EID: 84880509237     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12135     Document Type: Article

References (40)

1. Cohen, S.H., D.N. Gerding, S. Johnson, et al. 2010. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31: 431-455.
2. Rupnik, M., M.H. Wilcox & D.N. Gerding. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7: 526-536.
3. Karas, J.A., D.A. Enoch & S.H. Aliyu. 2010. A review of mortality due to Clostridium difficile infection. J. Infect. 61: 1-8.
4. Black, S.R., K.N. Weaver, R.C. Jones, et al. 2011. Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. Infect. Control Hosp. Epidemiol. 32: 897-902.
5. Al-Abed, Y.A., E.A. Gray & N.D. Rothnie. 2010. Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. Surgeon 8: 330-333.
6. Grundfest-Broniatowski, S., M. Quader, F. Alexander, et al. 1996. Clostridium difficile colitis in the critically ill. Dis. Colon Rectum. 39: 619-623.
7. Kyne, L., C. Merry, B. O'Connell, et al. 1999. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing. 28: 107-113.
8. Louie, T.J., M.A. Miller, K.M. Mullane, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364: 422-431.
9. Cornely, O.A., D.W. Crook, R. Esposito, et al. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12: 281-289.
10. Weiss, K. 2009. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 33: 4-7.
11. Zar, F.A., R. Srinivasa, K. Bakkanagari, et al. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302-307.
12. Aslam, S., R.J. Hamill & D.M. Musher. 2005. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infec. Dis. 5: 549-557.
13. McFarland, L.V., C.M. Surawicz, M. Rubin, R. Fekety, G.W. Elmer & R.N.Greenberg. 1999. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20: 43-50.
14. Khanna, S., D.S. Pardi, S.L. Aronson, et al. 2012. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 107: 89-95.
15. Kutty, P.K., S.R. Benoit, C.W. Woods, et al. 2008. Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005. Infect. Control Hosp. Epidemiol. 29: 197-202.
16. Hookman, P. & J.S. Barkin. 2009. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 15: 1554-1580.
17. Kelly, C.P. & J.T. LaMont. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359: 1932-1940.
18. Arvand, M., A.M. Hauri, N.H. Zaiss, et al. 2009. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro. Surveill. 14pii: 19403.
19. Bolton, R.P. & M.A. Culshaw. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27: 1169-1172.
20. Dallal, R.M., B.G. Harbrecht, A.J. Boujoukas, et al. 2002. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235: 363-372.
21. Muto, C.A., M. Pokrywka, K. Shutt, et al. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26: 273-280.
22. Pepin, J., L. Valiquette, M.E. Alary, et al. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 171: 466-472.
23. Loo, V.G., L. Poirier, M.A. Miller, et al. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353: 2442-2449.
24. Louie, T., M. Miller, C. Donskey, K. Mullane & E.J.C. Goldstein. 2009. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53: 223-228.
25. Kuijper, E.J., R.J. van den Berg, S. Debast, et al. 2006. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg. Infect. Dis. 12: 827-830.
26. Smith, A. 2005. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro. Surveill. 10: E050630-E050632.
27. Silversides, A. 2008. Ontario's hospitals surpass those of Quebec in C. difficile rates. Can. Med. Assoc. J. 178: 1649.
28. Jump, R.L., M.M Riggs, A.K. Sethi, et al. 2010. Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA. Emerg. Infect. Dis. 16: 827-829.
29. Kuijper, E.J., F. Barbut, J.S. Brazier, et al. 2008. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 13: pii: 18942.
30. Artsimovitch, I., J. Seddon & P. Sears. 2012. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 55: S127-S131.
31. Goldstein E.J., F. Babakhani & D.M. Citron. 2012. Antimicrobial Activities of Fidaxomicin.Clin. Infect. Dis. 55(Suppl. 2): S143-S148.
32. Babakhani, F., A. Gomez, N. Robert & P. Sears. 2011. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob. Agents Chemother. 55: 4427-4429.
33. Finegold, S.M., D. Molitoris, M.L. Vaisanen, et al. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48: 4898-4902.
34. Credito, K.L. & P.C. Appelbaum. 2004. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 20: 4430-4434.
35. Tannock, G.W., K. Munro, C. Taylor, et al. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156: 3354-3359.
36. Louie, T.J., K. Cannon, B. Byrne, et al. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin repression and recurrence of CDI. Clin. Infect. Dis. 55(Suppl. 2): S132-S142.
37. Babakhani, F., L. Bouillaut, A. Gomez, P. Sears, L. Nguyen & A.L. Sonenshein. 2012. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55: S162-S169.
38. Babakhani, F., L. Bouillaut, P. Sears, et al. 2013. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68: 515-522.
39. Cornely, O.A., M.A. Miller, T.J. Louie, et al. 2012. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55: S154-S161.
40. Mullane, K.M., M.A. Miller, K. Weiss, et al. 2011. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53: 440-447.